Table 1.
Clinical trials of carotuximab (TRC105) use against liver diseases.
| Trial Description |
Condition or Disease | FDA Approval Status | NCT# |
|---|---|---|---|
| Sorafenib and | Hepatoma | Phase 1/2 | NCT01306058 |
| TRC105 in | Liver neoplasms | ||
| hepatocellular | Adenoma, liver | ||
| cancer | hepatocellular carcinoma | ||
| Liver neoplasms, experimental |
|||
| TRC105 for | Hepatocellular carcinoma | Phase 2 | NCT01375569 |
| liver cancer | Hepatocellular cancer | ||
| that has not responded to sorafenib |
Carcinoma, hepatocellular | ||
| Trial of TRC105 and sorafenib in patients with HCC | Hepatocellular carcinoma | Phase 1/2 | NCT02560779 |
Treatment with NCT01306058 and NCT02560779 include sorafenib and TRC105. Treatment of NCT01375569 only includes TRC105. Condition or disease: the disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as life span, quality of life and health risks (data from clinicaltrials.gov and TRC105 were searched using Ingenuity Pathway Analysis). NCT#: National Clinical Trial number.